PMID- 16399226
OWN - NLM
STAT- MEDLINE
DCOM- 20060309
LR  - 20111117
IS  - 0304-3835 (Print)
IS  - 0304-3835 (Linking)
VI  - 231
IP  - 2
DP  - 2006 Jan 18
TI  - The effect of a therapeutic dendritic cell-based cancer vaccination depends on 
      the blockage of CTLA-4 signaling.
PG  - 247-56
AB  - Dendritic cells (DCs) were pulsed with the H-2K(b) binding OVA(257-264)-peptide 
      (SIINFEKL), and used as one single-injection vaccine in combination with 
      anti-CTLA-4 monoclonal antibody (mAb) to treat mice inoculated 3 days previously 
      with 3x10(5) E.G7-OVA lymphoma cells. Neither DC vaccination nor CTLA-4 blockage 
      alone prevented tumor growth in tumor challenged mice. In contrast, the 
      combination of one vaccination and injection of anti-CTLA-4 mAb lead to rejection 
      or retarded tumor growth in more than 60% of the mice. The OVA-transgene or the 
      SIINFEKL-epitope was not lost in the progressing tumors of vaccinated mice, 
      however, the highest degree of anti-SIINFEKL reactivity of host CTLs in an 
      IFN-gamma ELISPOT assay was found only in mice showing complete tumor rejection. 
      Vaccinated mice having rejected E.G7-OVA tumors were capable of rejecting 
      subsequent challenges with 1x10(6) E.G7-OVA tumor cells, and later on these mice 
      even rejected wild-type EL-4 tumor cells indicating that tumor epitope spreading 
      takes place during the process of vaccination-induced E.G7-OVA rejection. In 
      agreement with these observations, mice having rejected E.G7-OVA tumors showed 
      long lasting CTL memory in spleen and bone marrow towards both the 
      SIINFEKL-peptide and other EL-4-derived tumor rejecting epitopes.
FAU - Met, Ozcan
AU  - Met O
AD  - Department of Medical Anatomy, The Panum Institute, The University of Copenhagen, 
      Blegdamsvej 3, Copenhagen 2200N, Denmark. ome@mai.ku.dk
FAU - Wang, Mingjun
AU  - Wang M
FAU - Pedersen, Anders E
AU  - Pedersen AE
FAU - Nissen, Mogens H
AU  - Nissen MH
FAU - Buus, Soren
AU  - Buus S
FAU - Claesson, Mogens H
AU  - Claesson MH
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation)
RN  - 0 (CTLA-4 Antigen)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Ctla4 protein, mouse)
RN  - 0 (Egg Proteins)
RN  - 0 (Epitopes)
RN  - 0 (H-2 Antigens)
RN  - 0 (H-2Kb protein, mouse)
RN  - 0 (OVA-8)
RN  - 0 (Peptide Fragments)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/pharmacology
MH  - Antigens, CD
MH  - Antigens, Differentiation/*immunology
MH  - Bone Marrow/immunology
MH  - CTLA-4 Antigen
MH  - Cancer Vaccines/*therapeutic use
MH  - Dendritic Cells/*immunology
MH  - Drug Therapy, Combination
MH  - Egg Proteins/immunology
MH  - Epitopes/immunology
MH  - Female
MH  - H-2 Antigens/metabolism
MH  - Lymphoma/*drug therapy/immunology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Ovalbumin/immunology
MH  - Peptide Fragments/immunology/*therapeutic use
MH  - Signal Transduction
MH  - Spleen/immunology
MH  - T-Lymphocytes, Cytotoxic/drug effects/immunology
MH  - Thymoma/*drug therapy/immunology
MH  - Transgenes/physiology
MH  - Vaccination
EDAT- 2006/01/10 09:00
MHDA- 2006/03/10 09:00
CRDT- 2006/01/10 09:00
PHST- 2005/01/10 00:00 [received]
PHST- 2005/02/01 00:00 [revised]
PHST- 2005/02/04 00:00 [accepted]
PHST- 2006/01/10 09:00 [pubmed]
PHST- 2006/03/10 09:00 [medline]
PHST- 2006/01/10 09:00 [entrez]
AID - S0304-3835(05)00097-2 [pii]
AID - 10.1016/j.canlet.2005.02.005 [doi]
PST - ppublish
SO  - Cancer Lett. 2006 Jan 18;231(2):247-56. doi: 10.1016/j.canlet.2005.02.005.